RECOMBINANT HUMAN GROWTH HORMONE (NUTROPIN) IN POST RENAL TRANSPLANTED CHILDREN

肾移植后儿童的重组人类生长激素（NUTROPIN）

• 批准号: 6279615
• 负责人: ROBERT Bruce ETTENGER
• 金额: $ 1.77万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6279615
• 关键词: body height; child physical development; clinical research; drug screening /evaluation; homologous transplantation; human subject; kidney transplantation; pediatric pharmacology; postoperative state; recombinant proteins; somatotropin; transplant rejection

The specific aims of this study are to 1) determine if treatment of growth retarded renal transplant recipients treated with Nutropin will have acceleration of growth velocity and improvemnet in standardized height (SDS) and 2) determine if treatment of pediatric renal transplant patients with Nutropin will result in the development or progression of acute allograft dysfunction or chronic rejection as measured by a significant change in allograft function.

本研究的具体目的是 1) 确定治疗是否 使用 Nutropin 治疗的生长迟缓的肾移植受者将 增长速度加快，标准化水平不断提高 身高（SDS）和2）确定是否进行小儿肾移植治疗 Nutropin 患者将导致以下疾病的发生或进展： 急性同种异体移植功能障碍或慢性排斥反应 同种异体移植物功能发生显着变化。